Israel, Teva Pharmaceutical Headquarters.
CEO Schultz convened a meeting with the heads of various laboratories.
The secretary distributed a document to all attendees.
Schultz's face was clouded with gloom as he said in a deep voice, "Gentlemen, please take a look at this document in your hands. It is a message sent back by Teva's China branch. Three Purities, the leading pharmaceutical company in the East, has launched China's first generic version of Glatiramer."
The crowd erupted in uproar and began to discuss the matter.
"Three Purities? Is it the Three Purities that develops Anti-cancer Drug and AD Special Effect Drug? Is it also going to enter the generic drug field?"
"Glatiramer is our flagship product. Its patent expired five years ago, which led to a joint attack from two generic drug giants, Sandoz and Mylan. This has already caused the company's stock price to plummet and had a significant impact on the market. If another powerful pharmaceutical company from the East joins the fray, it will cause serious damage to the company's sales."
"Damn it, generic drugs from the East are known for being cheap, which will be a huge blow to our original drugs."
"Why would Three Purities's generic drugs have the same efficacy and quality as our original drugs? This is not scientific."
"It seems they have invested a lot of research and development resources in this to achieve such results, which will definitely take away a lot of our market share."
"Three Purities has both money and technology, and will be our biggest enemy in the field of generic drugs."
Glatiramer is a first-line drug developed by Teva Industries for the treatment of Multiple Sclerosis. It ranks 17th among the world's best-selling drugs, with sales exceeding $4 billion for five consecutive years, making it the top drug for multiple sclerosis and a blockbuster drug for Rare Disease.
The global market for Multiple Sclerosis drugs is approximately $20 billion. The Eagle Country is the largest market for these drugs.
Multiple Sclerosis) is a chronic central nervous system (brain and spinal cord) disease that primarily affects young adults aged 20-40. Its exact cause is unknown, but internationally it is believed to be related to autoimmunity. Clinical manifestations include numbness in the limbs, optic neuritis leading to vision loss or even blindness, and motor abnormalities causing difficulty walking or even paralysis. The malignancy of this disease is comparable to that of neurotumors.
Schultz's hawk-like gaze swept across the room as he slowly spoke, "The only good news is that due to the short timeframe, this generic drug is mainly being marketed in China and has not yet received FDA approval to enter the Eagle Country market."
"Gentlemen, you need to go all out to develop upgraded products. Right now, all we have to compete with cheap generic drugs is the long-acting Glatiramer, which is far from enough."
"Three Purities's R&D capabilities are beyond doubt, ranking among the world's top. Their move into the generic drug field will surely stir up a storm."
"The global generic drug market needs to understand one thing: the wolf is coming."
"We must make changes, and we should take advantage of the stock price drop to carry out global layoffs. My plan is to lay off 10,000 employees first to reduce operating and management costs. After the stock price rises, we can then acquire new companies with complementary businesses to enrich our product line and survive in the fierce competition."
The heads of the various laboratories looked serious and nodded in agreement.
******
India, Mumbai, Sun Pharma Headquarters.
India is a remarkable country with an incredibly developed generic drug industry. It not only meets its own domestic drug needs but also exports its products overseas, firmly holding 40% of the generic drug market in the Eagle Country.
Drugs that originally cost several thousand yuan can be sold for only a few hundred yuan in India as generic versions, and drugs that originally cost several hundred yuan can even be sold for just a few yuan per tablet in India generic versions.
The reason it's so cheap is twofold: firstly, the production cost is low, and secondly, it receives government support, ignoring pharmaceutical patents.
The government, standing on the moral high ground, said that if medicines were too expensive, people would die because they couldn't afford them. Therefore, in order to save people's lives, it allowed the production of generic versions of foreign patented drugs.
As long as the manufacturing process of the generic drug differs from that of the original, it's fine. In other words, the original is cooked with water, while this one is cooked with soup, thus bypassing the manufacturing process patent.
Therefore, even if the patented drug is still under protection, India Pharmaceutical Company can openly infringe on its patents and produce generic versions. Moreover, India Pharmaceutical Company always chooses the newest and most effective drugs to produce generic versions, which makes European Eagle Pharmaceutical Company, which invests a lot in research and development, grit its teeth in anger.
Besides generic drugs, India also boasts a very high level of medical care. Many wealthy people from developed countries choose to travel to India for medical treatment, such as organ transplants.
Even global pharmaceutical giants often set up branches in India to conduct various clinical trials. After developing new drugs, they will quickly license them to generic drug companies in India at low prices.
Because clinical trials in India are very inexpensive and have low requirements, it is easy to recruit participants for drug trials. Even if the participants are harmed by the trials, the compensation is very low. In short, this low human rights advantage makes major global pharmaceutical companies unable to resist India's cheap clinical environment, so they have tacitly accepted this practice, which can be considered a win-win situation.
India was also very sensible; those patent-infringing generic drugs would not be sold in developed countries, and the two sides reached a tacit understanding.
As a result, India's generic drug industry flourished, giving rise to many generic drug giants.
Sun Pharma is the Big Brother Leader in India's generic drug industry, the world's fifth largest generic drug company, and the number one India pharmaceutical company in the Eagle Country market, with total annual revenue of approximately US$4 billion.
While not as profitable as top pharmaceutical companies like Pfizer, Bayer, Roche, and Novartis, it still maintains a 10% profit margin.
At this moment, Sun Pharma's president Sanghavi, was sitting in his office at headquarters, feeling extremely bad.
Outside the window, the sun shone brightly in the clear sky, but in his heart, a storm was brewing.
The latest sales reports were laid out on his large desk, and the more he looked at them, the angrier he became.
A knock sounded at the door, and several company executives filed in. Seeing his gloomy face, they felt a chill run down their spines.
Sanghavi finally couldn't hold back any longer, threw the report in his hand at the people opposite him, and roared loudly.
"Why have the sales of these generic drugs declined so drastically? I need an explanation!"
The sales director forced a smile and said, "The main problem is the severe decline in sales of our generic versions of Tregolide and Bosentan tablets. The reason is that Three Purities, a giant in the pharmaceutical industry, started making generic drugs, so we quickly lost the China market."
The R&D director picked up the report and looked at it carefully for a while, his expression serious.
"The patent for Bosentan tablets has expired. Previously, China did not have generic versions, so they all bought our generic versions because the original drug was expensive, 4,000 yuan a box, while ours was only 400 yuan a box. But this Three Purities has managed to bring the price down to 300 yuan, which we simply cannot compete with."
"There's also Sakura Country Takeda Pharmaceutical's long-acting Blood-Sugar-Lowering Drug, Tregolide, which hasn't been patented in China. This gave Three Purities an opportunity to take advantage of the situation. Patients used to buy the original drug from Sakura Country through agents, which cost 5,000 yuan per box. Our generic drug only costs 1,000 yuan, but this damn Three Purities actually lowered the price to 600 yuan. It's outrageous."
"These drugs don't have Patent Fee, only production costs. It's really unexpected that Three Purities can lower the price so much. I can't understand why it's selling so cheaply." The R&D director looked puzzled and couldn't figure it out.
In their view, although generic drugs are cheaper, they still have costs and need to make a profit. Basically, they should be more than half the price of the original drug. There is no need to lower the price so much, which is unreasonable.
"Moreover, Three Purities's generic drugs are more effective than ours, achieving 100% of the original drug's efficacy, with very few side effects, and yet they are sold at such a low price, which is simply outrageous. I can't imagine how they do it."
The R&D director became increasingly alarmed as he looked at the document, his face filled with disbelief.
Although India has advanced technology in producing generic drugs, it cannot achieve 100% replication of the original drug's efficacy.
The technological gap was too large, and coupled with the lack of price advantage, he finally understood why he had lost the China market.
Bosentan tablets are one of the main drugs for treating Pulmonary Hypertension, Rare Disease. They can effectively improve patients' exercise capacity and reduce clinical deterioration. Like Tregolide for treating Type II Diabetes, it is not subject to patent issues and is a flagship generic drug of Sun Pharma. It is also very popular in the Eagle Country market.
After a moment of contemplation, Sanghavi issued the order without any expression.
"As an innovative pharmaceutical company, Three Purities certainly has strong R&D capabilities, so it's not surprising that their generic drugs have performed this well. However, I heard that they are now focusing on generic versions of Rare Disease drugs and drugs that China has not yet launched, so the blow to us is not too great. We still have other opportunities."
"We need to avoid direct confrontation and sell more drugs like Gilead's third generation and HIV Triad. The patents for these drugs haven't expired yet, and according to China law, Three Purities) cannot be copied, so it won't affect our sales."
"As for drugs whose patents have expired, we should try our best to be the first to market a generic version, and then immediately push for its launch in the Eagle Country. Do you understand?"
Everyone nodded, their mood becoming heavy.
They knew in their hearts that Three Purities would definitely not be satisfied with these two generic drugs and would continue to expand its territory in the generic drug market.
In the generic drug field, a lone wolf has emerged.
This industry is already highly competitive with thin profit margins, so this will inevitably lead to a round of fierce competition and a reshuffling of the industry.
So, who will be the first unlucky one to fall?
Hopefully it's not Sun Pharma.